Search
Berotralstat
go.drugbank.com/drugs/DB15982ApprovedInvestigationalBerotralstat is a selective inhibitor of plasma kallikrein used in the prophylaxis of attacks of hereditary angioedema (HAE). It works by blocking the enzymatic activity of plasma kallikrein in releasing bradykinin, the major biologic pe...
Categories: Cytochrome P-450 CYP2D6 Inhibitors, P-glycoprotein inhibitorsAtogepant
go.drugbank.com/drugs/DB16098ApprovedInvestigationalAtogepant is an oral antagonist of calcitonin gene-related peptide (CGRP) receptors indicated for the prevention of episodic migraine headaches. It was developed by AbbVie and received FDA approval under the brand name Qulipta in Septemb...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesDelgocitinib
go.drugbank.com/drugs/DB16133ApprovedInvestigationalDelgocitinib is a pan-Janus kinase (JAK) inhibitor. After the first global approval in Japan, delgocitinib was also approved by the European Commission on September 23, 2024. It works to reduce the inflammatory response in inflammatory s...
Categories: P-glycoprotein substratesLazertinib
go.drugbank.com/drugs/DB16216ApprovedInvestigationalLazertinib is an oral, third-generation, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Lazertinib was first approved in South Korea on January 18, 2021, for the treatment of EGFR T790M mutation-positive non-sma...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsAlmonertinib
go.drugbank.com/drugs/DB16640ApprovedInvestigationalAlmonertinib is a third-generation EGFR tyrosine kinase inhibitor targeting EGFR-sensitizing and T790M resistance mutations. Unlike other third-generation EGFR TKIs, almonertinib is a pyrimidine-based drug that forms a covalent bond to t...
Categories: Cytochrome P-450 CYP1A2 Inducers, P-glycoprotein inhibitorsRemibrutinib
go.drugbank.com/drugs/DB16852ApprovedInvestigationalRemibrutinib is a selective Bruton's tyrosine kinase inhibitor. The FDA approved remibrutinib on September 30, 2025 as the only oral, targeted treatment for chronic spontaneous urticaria. Bruton's tyrosine kinase plays a role in B cell r...
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP2B6 InducersLinzagolix
go.drugbank.com/drugs/DB17083ApprovedInvestigationalLinzagolix is a non-peptide, selective antagonist of the gonadotropin-releasing hormone (GnRH) receptor. It has been studied for the treatment of estrogen-dependent conditions such as uterine fibroids and endometriosis. It is similar to ...
Categories: Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 SubstratesZiftomenib
go.drugbank.com/drugs/DB17171ApprovedInvestigationalZiftomenib is a potent and highly selective menin inhibitor. This drug was approved by the FDA on November 13th, 2025, for the treatment of relapsed or refractory acute myeloid leukemia (AML) in adults with a susceptible NPM1 mutation wh...
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 SubstratesPirtobrutinib
go.drugbank.com/drugs/DB17472ApprovedInvestigationalPirtobrutinib is a small molecule and a highly selective non-covalent inhibitor of Bruton’s tyrosine kinase (BTK). Its high selectivity has been associated with lower discontinuation rates due to adverse events and a lower incidence of a...
Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP1A2 InhibitorsVimseltinib
go.drugbank.com/drugs/DB17520ApprovedInvestigationalVimseltinib is a small molecule kinase inhibitor targeting colony-stimulating factor 1 receptor (CSF1R). It is highly selective, with a >500-fold selectivity for CSF1R over its nearest off-target kinase. It is intended to provide a sa...
Categories: P-glycoprotein inhibitors, P-glycoprotein substrates